IL-2alpha receptor subunit binding compounds
Peptidyl IL-2Rα ligands and compounds comprising the IL-2Rα ligands are disclosed. The IL-2Rα ligands and compounds such as synthetic monomers, homodimers, or heteromers and recombinant fusion proteins comprising the IL-2Rα ligands can be used as targeting or imaging agents, as diagnostics or to treat cancers and autoimmune diseases.
1. An IL-2Rα ligand, wherein,
the IL-2Rα ligand binds to the human IL-2Rα subunit with an IC 50 of less than 100 μM; and
the IL-2Rα ligand comprises an amino acid sequence selected from any one of SEQ ID NOS: 4, 9, 24, 31, 44, 50, 67, 79, 100, 112, 135, 144, 154, 172, 180, 203, 210, 219, 234, 250, and 418:
SEQ ID NO: 4
F L H W P V Y F C Q V M
SEQ ID NO: 9
F I P W D E Y F K Q V L
SEQ ID NO: 24
F V H C T L L G C W S G
SEQ ID NO: 31
W V I C S A V G C R P F
SEQ ID NO: 44
H V I C S V N G G C R G
SEQ ID NO: 50
E Q F C L V S D P M A C W S L
SEQ ID NO: 67
R R F C L R S E P A A C W F V
SEQ ID NO: 79
S K C V Y D Y N F G T C I F
SEQ ID NO: 100
S L N C K T R P G L R W C T W T
SEQ ID NO: 112
A W E C L F L P G H R G C S L F
SEQ ID NO: 135
R Q F C L V S P G Y E D C W F V
SEQ ID NO: 144
S A C Q L K W D E G W T C L F
SEQ ID NO: 154
R G C S L V W S G S W E C I F
SEQ ID NO: 172
G C T L S W N Q G W W H C V
SEQ ID NO: 180
A R C S L H H T G S R Y E C I F
SEQ ID NO: 203
T C R L K R S G P N S W E C I
SEQ ID NO: 210
V R C R L A R P G L T W E C L S
SEQ ID NO: 219
Q L C P W S D P G S W G P C P L
SEQ ID NO: 234
G C Q L V W Q D D S Y M C F Y
SEQ ID NO: 250
W C I G Q P L F R Q G S C K
SEQ ID NO: 418
F V P W D V Y F S Q I L G G.
2. The IL-2Rα ligand of claim 1 , wherein the IL-2Rα ligand comprises the amino acid sequence of SEQ ID NO: 4.
3. The IL-2Rα ligand of claim 1 , wherein the IL-2Rα ligand comprises the amino acid sequence of SEQ ID NO: 9.
4. The IL-2Rα ligand of claim 1 , wherein the IL-2Rα ligand comprises the amino acid sequence of SEQ ID NO: 24.
5. The IL-2Rα ligand of claim 1 , wherein the IL-2Rα ligand comprises the amino acid sequence of SEQ ID NO: 31.
6. The IL-2Rα ligand of claim 1 , wherein the IL-2Rα ligand comprises the amino acid sequence of SEQ ID NO: 44.
7. The IL-2Rα ligand of claim 1 , wherein the IL-2Rα ligand comprises the amino acid sequence of SEQ ID NO: 50.
8. The IL-2Rα ligand of claim 1 , wherein the IL-2Rα ligand comprises the amino acid sequence of SEQ ID NO: 67.
9. The IL-2Rα ligand of claim 1 , wherein the IL-2Rα ligand comprises the amino acid sequence of SEQ ID NO: 79.
10. The IL-2Rα ligand of claim 1 , wherein the IL-2Rα ligand comprises the amino acid sequence of SEQ ID NO: 100.
11. The IL-2Rα ligand of claim 1 , wherein the IL-2Rα ligand comprises the amino acid sequence of SEQ ID NO: 112.
12. The IL-2Rα ligand of claim 1 , wherein the IL-2Rα ligand comprises the amino acid sequence of SEQ ID NO: 135.
13. The IL-2Rα ligand of claim 1 , wherein the IL-2Rα ligand comprises the amino acid sequence of SEQ ID NO: 144.
14. The IL-2Rα ligand of claim 1 , wherein the IL-2Rα ligand comprises the amino acid sequence of SEQ ID NO: 154.
15. The IL-2Rα ligand of claim 1 , wherein the IL-2Rα ligand comprises the amino acid sequence of SEQ ID NO: 172.
16. The IL-2Rα ligand of claim 1 , wherein the IL-2Rα ligand comprises the amino acid sequence of SEQ ID NO: 180.
17. The IL-2Rα ligand of claim 1 , wherein the IL-2Rα ligand comprises the amino acid sequence of SEQ ID NO: 203.
18. The IL-2Rα ligand of claim 1 , wherein the IL-2Rα ligand comprises the amino acid sequence of SEQ ID NO: 210.
19. The IL-2Rα ligand of claim 1 , wherein the IL-2Rα ligand comprises the amino acid sequence of SEQ ID NO: 219.
20. The IL-2Rα ligand of claim 1 , wherein the IL-2Rα ligand comprises the amino acid sequence of SEQ ID NO: 234.
21. The IL-2Rα ligand of claim 1 , wherein the IL-2Rα ligand comprises the amino acid sequence of SEQ ID. NO: 250.
22. The IL-2Rα ligand of claim 1 , wherein the IL-2Rα ligand comprises the amino acid sequence of SEQ ID. NO: 418.
23. A compound comprising at least one IL-2Rα ligand of claim 1 .
24. The compound of claim 23 , wherein the compound is selected from a peptide, a conjugate, and a fusion protein.
25. A pharmaceutical composition comprising the IL-2Rα ligand of claim 1 .
26. A pharmaceutical composition comprising the compound of claim 23 .